The DOI matches its Crossref record; 107 of the 109 references it cites were found in a registry or an index.
Psychiatric risks for worsened mental health after psychedelic use
Open accessAbstract
Background: Resurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited by biases and small sample sizes. The current analytical approach was motivated by the question of whether rare but significant adverse effects have been under-sampled in psychedelic research studies. Methods: A “bottom margin analysis” approach was taken to focus on negative responders to psychedelic use in a pool of naturalistic, observational prospective studies ( N = 807). We define “negative response” by a clinically meaningful decline in a generic index of mental health, that is, one standard error from the mean decrease in psychological well-being 4 weeks post-psychedelic use (vs pre-use baseline). We then assessed whether a history of diagnosed mental illness can predict negative responses. Results: We find that 16% of the cohort falls into the “negative responder” subset. Parsing the sample by self-reported history of psychiatric diagnoses, results revealed a disproportionate prevalence of negative responses among those reporting a prior personality disorder diagnosis (31%). One multivariate regression model indicated a greater than four-fold elevated risk of adverse psychological responses to psychedelics in the personality disorder subsample ( b = 1.425, p < 0.05). Conclusion: We infer that the presence of a personality disorder may represent an elevated risk for psychedelic use and hypothesize that the importance of psychological support and good therapeutic alliance may be increased in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additional reported concerns include the risk of emotional instability during sessions, challenges to establishing therapeutic rapport, and difficulty integrating psychedelic experiences (17–19).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One naturalistic, uncontrolled study found that individuals with personality disorders were over four times more likely to experience worsened mental health following psychedelic use of psilocybin, lysergic acid diethylamide (LSD)), ayahuasca, N,N-Dimethyltryptamine (DMT)), mescaline, and iboga (17).”
From Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
A very brief measure of the Big-Five personality domains
Gosling, S. D., Rentfrow, P. J., & Swann, W. B. (2003) · Journal of Research in Personality · doi:10.1016/s0092-6566(03)00046-1 · Cited by 8,307 · cited 4×
“Given the heterogeneity between different PD diagnoses, aimed to understand the profile of participants with self-reported PD, as per a univariate regression on the Ten-Item Personality Inventory (TIPI) elements (Gosling et al., 2003) (Supplemental Table 1).”
MethodInfluentialCognitive-Behavioral Treatment of Borderline Personality Disorder
Cary, G. L. (1994) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1994.48.1.155 · Cited by 6,283
The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., Parkinson, J., Secker, J., & Stewart-Brown, S. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-63 · Cited by 5,031
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…of psychedelic therapy as a treatment for a wide range of psychiatric disorders, from major depressive disorder (MDD) to addiction, obsessive-compulsive disorder (OCD), end-of-life anxiety, etc. (Bogenschutz et al., 2015; Carhart-Harris et al., 2021b; Griffiths et al., 2016; Moreno et al., 2006).”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“In accordance with the current exclusion criteria of psy-chedelic clinical trials (Carhart-Harris et al., 2016, 2021b), we found that the highest proportion of negative responders was in a group of individuals with a history of PD diagnosis (31%, i.e., 5 cases of 16, Table 2).”
BackgroundSelf-citationThe Revised NEO Personality Inventory (NEO-PI-R)
Costa, P. T., & McCrae, R. R. (2008) · The SAGE Handbook of Personality Theory and Assessment: Volume 2 — Personality Measurement and Testing · doi:10.4135/9781849200479.n9 · Cited by 1,463 · cited 1×
“…within our cohort, we assessed for correlations with individual items in the TIPI (Gosling et al., 2003), measuring the five major personality domains: openness to experience, extraversion, agreeableness, conscientiousness, and emotional stability (inverse of neuroticism) (Costa and McCrae, 2008).”
MethodTrial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Self-citationStewart-Brown, S., Tennant, A., Tennant, R., Platt, S., Parkinson, J., & Weich, S. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-15 · Cited by 1,251
Research works printed but not linked: 7
- American Psychiatric Association, 1987, DSM III-R. Diagnostic and Statistical Manual of Mental Disorders—Third Revised Version
- Biskin RS, 2013, Psychiatric Times, 30, 29
- Grinspoon L, 2001, Social Research, 68, 677
- Iliff J, 2022, Journal of Addiction Science, 8, 10
- Kahneman D, 2011, Thinking, Fast and Slow
- Nandan NK, 2022, Cureus, 14, e24632
- 10.1001/jama.1966.03110060063015 · doi:10.1001/jama.1966.03110060063015
Cited by
Weiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 74
“Moreover, psychedelics might prove harmful in those conditions, which are typically characterized by baseline deficits in various complexity levels of self-representation (e.g., subjects at high risk for psychosis or subjects with a borderline personality organization) [121,128].”
Pellegrini, L., Fineberg, N. A., O'Connor, S., de Souza, A. M. F. L. P., Godfrey, K., Reed, S., Peill, J. M., Healy, M., Rohani-Shukla, C., Lee, H., et al. (2025) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2025.152619 · Cited by 29
“While psilocybin is generally regarded as safe when administered in controlled environments [24], there are concerns regarding its potential to induce adverse psychological effects, particularly in individuals with a history of bipolar disorder or psychosis [24 – 26].”
Self-citationWalther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 22
“While cases in the literature might seem rare, there is a realistic possibility that they are overlooked or under-reported due to flawed designs, small sample sizes, imprecise follow-ups, or biased reporting [202].”
Elfrink, S., & Bergin, L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1528253 · Cited by 20
“Furthermore, personality disorders, which are frequently associated with trauma, constitute another significant risk factor for adverse psychological events following psychedelic use (Yuan et al., 2023; Marrocu et al., 2024).”
Psychedelic-related deaths in England, Wales and Northern Ireland (1997–2022)
Kopra, E. I., Penttinen, J., Rucker, J., & Copeland, C. S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111177 · Cited by 13
Metadata
- Authors
- Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L.
- Affiliations
- Imperial College London (GB)
- NYU Langone Health (US)
- Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK
- University of California, San Francisco (US)
- Corresponding author
- Kettner, Hannes
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2024-03
- Volume
- 38
- Issue
- 3
- Pages
- 225-235
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC10944581
- OpenAlex
- W4392369508
- Cited by
- 60
- References
- 109
- Citations by year
- 2026: 19 · 2025: 33 · 2024: 8
- FWCI
- 30.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Centre for Psychedelic Research
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- psychedelic use, personality disorders, history of mental illness, psychological well-being, therapeutic relationship
- MeSH terms
- Mental Disorders, Hallucinogens, Humans, Mental Health, Prospective Studies, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychiatric risks for worsened mental health after psychedelic use. https://app.cochat.ai/papers/10.1177/02698811241232548
- The paper
- Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L. (2024). Psychiatric risks for worsened mental health after psychedelic use. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241232548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.